A COMPOSITE METRIC TO IDENTIFY HFPEF PATIENTS LIKELY TO BENEFIT FROM SPIRONOLACTONE
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)31308-5
Abstract: The TOPCAT trial, overall, showed no benefit for spironolactone in heart failure patients with preserved ejection fraction (HFpEF). Post-hoc, spironolactone helped participants from the Americas but not Eastern Europe, potentially due to differences in baseline… read more here.
Keywords: identify hfpef; composite metric; hfpef patients; benefit spironolactone ... See more keywords